The recent discovery of vamorolone, an MR antagonist that is equally potent to eplerenone and also mirrors the anti-inflammatory benefits of corticosteroids, may represent a critical step toward the inclusion of this MR antagonist as a standard and proactive therapy for DMD cardiomyopathy [125]. This evidence concerns the gene NR3C2 and Duchenne muscular dystrophy.